Philippa Cheetham, MBChB, MRCS, MD, FRCS

May 05, 2021

Current hurdles faced by neurologists when prescribing therapy to treat migraine and advice to help other healthcare professionals as well as patients navigate insurance and access issues.

May 05, 2021

A patient advocate, Jill Dehlin, RN, explains why patients with migraine should connect with other patients via patient support programs and take a proactive role in managing their condition.

April 28, 2021

Advice to community neurologists and other care providers who may treat patients with migraine in the community setting on incorporating newer therapies, such as CGRP inhibitors, into practice, and a list of reputable resources where patients can turn for additional support.

April 28, 2021

Jill Dehlin, RN, describes her role as an advocate in supporting others with migraine and connecting them to the support and resources needed to best manage their condition.

April 21, 2021

The potential connection between risk of dementia in patients treated with triptans for migraine as compared to the safety profiles of newer CGRP monoclonal antibodies.

April 21, 2021

Jessica Ailani, MD, of MedStar Health, describes the mechanisms of action and indications for use of currently available CGRP inhibitors for migraine.

April 14, 2021

Jill Dehlin, RN, a patient with migraine, talks about her experience receiving a subcutaneous injectable CGRP inhibitor, and neurologist Jessica Ailani, MD, explains what she counsels her patients on when prescribing a newer injectable treatment. 

April 14, 2021

Jessica Ailani, MD, a neurologist from MedStar Health, shares insight on best practices for dosing therapies used to treat migraine and implications for combining drugs together.

April 07, 2021

Variables that neurologists and other healthcare professionals need to consider when selecting an appropriate prescription therapy for migraine, and recommendations by a patient advocate on staying adherent to therapy and predicting attacks.

April 07, 2021

Limitations, in terms of safety and efficacy, of older conventional therapies used to treat migraine.